Showing results (291-300 of 367) with videos related to
Sort By:
Pageof 37
Science Translational Medicine|September 17, 2025
PD-1-targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancerIrene Fusi, Clara Serger, Petra Herzig, et al.Cell Reports. Medicine|August 16, 2023
Selective targeting of IL2Rβγ combined with radiotherapy triggers CD8- and NK-mediated immunity, abrogating metastasis in HNSCCJacob Gadwa, Maria Amann, Thomas E Bickett, et al.Nature Biomedical Engineering|June 29, 2026
The evolving role of cytokines for CAR-T cell manufacturing and beyondMar Guaza-Lasheras, Johanna Nimmerfroh, Dominic Schwarz, et al.Mabs|March 18, 2016
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerJuergen M Schanzer, Katharina Wartha, Ekkehard Moessner, et al.Theranostics|February 14, 2022
Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagersAlvaro Teijeira, Itziar Migueliz, Saray Garasa, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 18, 2018
The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In VivoAdam Palazzo, Sylvia Herter, Laura Grosmaire, et al.Journal of Autoimmunity|November 18, 2018
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune diseaseLaurence B Peterson, Charles J M Bell, Sarah K Howlett, et al.Journal of Autoimmunity|December 3, 2014
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cellsCharles J M Bell, Yongliang Sun, Urszula M Nowak, et al.British Journal of Haematology|February 23, 2018
New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodiesSaskia Meyer, Mitchell Evers, Johannes H M Jansen, et al.Mabs|November 17, 2022
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic miceJerome Egli, Stefan Heiler, Felix Weber, et al.Pageof 37